EAM
PLRX icon

Eventide Asset Management’s Pliant Therapeutics PLRX Stock Holding History

Eventide Asset Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-42,499
Closed -$574K – 146
2021
Q4 		$574K Sell
42,499
-2,140,739
-98% -$34M 0.01% 146
2021
Q3 		$36.9M Sell
2,183,238
-288,654
-12% -$6.13M 0.49% 66
2021
Q2 		$72M Hold
2,471,892
– – 0.97% 38
2021
Q1 		$97.2M Sell
2,471,892
-366,233
-13% -$11.9M 1.44% 21
2020
Q4 		$64.5M Hold
2,838,125
– – 0.99% 33
2020
Q3 		$61.7M Hold
2,838,125
– – 1.21% 29
2020
Q2 		$88.4M Buy
+2,838,125
New +$75.3M 1.92% 12

Other funds holding PLRX

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Eventide Asset Management's PLRX Position: Q1 2022 in Review

Eventide Asset Management sold out of Pliant Therapeutics (PLRX) in Q1 2022, closing a stake of 42,499 shares — an estimated $574K sold.

Eventide Asset Management first reported a position in PLRX in Q2 2020 and held it in 7 quarters. The position peaked at $97.2M in Q1 2021. 92 funds tracked by Wall St. Rank hold PLRX as of Q1 2022.

  • Eventide Asset Management reported no remaining Pliant Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Eventide Asset Management sold 42,499 Pliant Therapeutics shares in Q1 2022, an estimated $574K.
  • Eventide Asset Management first reported a position in Pliant Therapeutics in Q2 2020 and held it in 7 quarters.
  • Eventide Asset Management's Pliant Therapeutics position peaked at $97.2M in Q1 2021.
  • 92 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2022.

Based on Eventide Asset Management's 13F filing for Q1 2022, filed 16 May 2022.